GUIDELINES
Free Access
British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012
V.A. Venning,
K. Taghipour,
M.F. Mohd Mustapa,
A.S. Highet, G. Kirtschig,
V.A. Venning
Department of Dermatology, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, U.K.
Search for more papers by this authorK. Taghipour
Department of Dermatology, Whittington Hospital, Magdala Avenue, London N19 5NF, U.K.
Search for more papers by this authorM.F. Mohd Mustapa
British Association of Dermatologists, Willan House, 4 Fitzroy Square, London W1T 5HQ, U.K.
Search for more papers by this authorG. Kirtschig
Vrije Universtiteit, PO Box 7057, Amsterdam NL-1007 MB, the Netherlands
Search for more papers by this authorV.A. Venning,
K. Taghipour,
M.F. Mohd Mustapa,
A.S. Highet, G. Kirtschig,
V.A. Venning
Department of Dermatology, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, U.K.
Search for more papers by this authorK. Taghipour
Department of Dermatology, Whittington Hospital, Magdala Avenue, London N19 5NF, U.K.
Search for more papers by this authorM.F. Mohd Mustapa
British Association of Dermatologists, Willan House, 4 Fitzroy Square, London W1T 5HQ, U.K.
Search for more papers by this authorG. Kirtschig
Vrije Universtiteit, PO Box 7057, Amsterdam NL-1007 MB, the Netherlands
Search for more papers by this authorVanessa Venning. E-mail: [email protected]
Funding sources None.
Conflicts of interest None declared.
V.A.V., K.T., A.S.H. and G.K. are members of the guideline development group, with technical support provided by M.F.M.M.
This is an updated guideline prepared for the British Association of Dermatologists’ (BAD) Clinical Standards Unit, made up of the Therapy & Guidelines (T&G) Subcommittee. Members of the Clinical Standards Unit are: J.R. Hughes (Chairman T&G), J. McLelland, A.J. McDonagh, S. Punjabi, D.A. Buckley, I. Nasr, V.J. Swale, C.E. Duarte Williams, P.M. McHenry, S. Wagle (British National Formulary), S. Amin (British National Formulary), R. Davis (British Dermatological Nursing Group), S.E. Haveron (BAD Scientific Administrator), M.F. Mohd Mustapa (BAD Clinical Standards Manager).
Guidelines produced in 2002 by the British Association of Dermatologists; reviewed and updated 2012.
Supporting Information
Appendix S1 Literature search strategies.
| Filename | Description |
|---|---|
| BJD_12072_sm_AppendixS1.doc87.5 KB | Supporting info item |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Bell HK, Ormerod AD. Writing a British Association of Dermatologists clinical guideline: an update on the process and guidance for authors. Br J Dermatol 2009; 160: 725–8.
- 2 Brouwers M, Kho ME, Browman GP et al. AGREE II: advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J 2010; 182: E839–42.
- 3 Langan SM, Smeeth L, Hubbard R et al. Bullous pemphigoid and pemphigus vulgaris – incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180.
- 4 Bertram F, Brocker EB, Zillikens D et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7: 434–40.
- 5 Marazza G, Pham HC, Scharer L et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861–8.
- 6 Bernard P, Vaillant L, Labeille B et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48–52.
- 7 Taghipour K, Chi CC, Vincent A et al. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case–control study. Arch Dermatol 2010; 146: 1251–4.
- 8 Bastuji-Garin S, Joly P, Lemordant P et al. Risk factors for bullous pemphigoid in the elderly: a prospective case–control study. J Invest Dermatol 2011; 131: 637–43.
- 9 Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case–control study. J Invest Dermatol 2011; 131: 631–6.
- 10 Chen YJ, Wu CY, Lin MW et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 2011; 165: 593–9.
- 11 Lee JJ, Downham TF. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol 2006; 5: 562–4.
- 12 Mullins PD, Choudhury SL. Enalapril and bullous eruptions. BMJ 1994; 309: 1411.
- 13 Perry A, Sparling JD, Pennington M. Bullous pemphigoid following therapy with an oral beta-blocker. J Drugs Dermatol 2005; 4: 746–8.
- 14 Hodak E, Ben-Shetrit A, Ingber A et al. Bullous pemphigoid – an adverse effect of ampicillin. Clin Exp Dermatol 1990; 15: 50–2.
- 15 Bordignon M, Belloni-Fortina A, Pigozzi B et al. Bullous pemphigoid during long-term TNF-alpha blocker therapy. Dermatology 2009; 219: 357–8.
- 16 Skandalis K, Spirova M, Gaitanis G et al. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012; 26: 249–53.
- 17 Bastuji GS, Joly P, Picard DC et al. Drugs associated with bullous pemphigoid: a case–control study. Arch Dermatol 1996; 132: 272–6.
- 18 Lloyd-Lavery A, Chi CC, Wojnarowska F et al. The associations between bullous pemphigoid and drug use: a UK case–control study. Arch Dermatol 2012; (in press).
- 19 Vodegel RM, de Jong MC, Meijer HJ et al. Enhanced diagnostic immunofluorescence using biopsies transported in saline. BMC Dermatol 2004; 4: 10.
- 20 Vaughan Jones SA, Palmer I, Bhogal BS et al. The use of Michel’s transport medium for immunofluorescence and immunoelectron microscopy in autoimmune bullous diseases. J Cutan Pathol 1995; 22: 365–70.
- 21 Roussel A, Benichou J, Randriamanantany ZA et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011; 147: 293–8.
- 22 Charneux J, Lorin J, Vitry F et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011; 147: 286–91.
- 23 Wieland CN, Comfere NI, Gibson LE et al. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol 2010; 146: 21–5.
- 24 Rzany B, Partscht K, Jung M et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002; 138: 903–8.
- 25 Stevenson CJ. Treatment in bullous diseases with corticosteroid drugs and corticotrophin. Br J Dermatol 1960; 72: 11–21.
- 26 Church R. Pemphigoid treated with corticosteroids. Br J Dermatol 1960; 72: 434–8.
- 27 Roujeau JC, Guillaume JC, Morel P et al. Plasma exchange in bullous pemphigoid. Lancet 1984; 2: 486–8.
- 28 Morel P, Guillaume JC. [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study]. Ann Dermatol Venereol 1984; 111: 925–8. (in French).
- 29 Guillaume JC, Vaillant L, Bernard P et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49–53.
- 30 Joly P, Roujeau JC, Benichou J et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321–7.
- 31 Siegel J, Eaglstein WH. High-dose methylprednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1984; 120: 1157–65.
- 32 Albrecht J, Werth VP. Practice gaps. Improving the care of our patients who are receiving glucocorticoid therapy. Arch Dermatol 2012; 148: 314–15.
- 33 Marzano AV, Trevisan V, Eller-Vainicher C et al. Evidence for vitamin D deficiency and increased prevalence of fractures in autoimmune bullous skin diseases. Br J Dermatol 2012; 167: 688–91.
- 34 Tee SI, Yosipovitch G, Chan YC et al. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Arch Dermatol 2012; 148: 307–14.
- 35 Garg V, Jusko WJ. Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm Drug Dispos 1994; 15: 163–72.
- 36 Rollin C, Chosidow O, Diquet B et al. Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. Eur J Clin Pharmacol 1993; 44: 395–9.
- 37 Zimmermann R, Faure M, Claudy A. Prospective study of treatment of bullous pemphigoid by a class I topical corticosteroid. Ann Dermatol Venereol 1999; 126: 13–16.
- 38 Joly P, Roujeau JC, Benichou J et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009; 129: 1681–7.
- 39 Kirtschig G, Middleton P, Bennett C et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010; 10: CD002292.
- 40 Taghipour K, Mohd Mustapa MF, Highet AS et al. The approach of UK dermatologists to the treatment of bullous pemphigoid – results of a national survey. Clin Exp Dermatol 2012; (in press).
- 41 Burton JL, Harman RR, Peachey RD et al. Azathioprine plus prednisone in treatment of pemphigoid. BMJ 1978; 2: 1190–1.
- 42 Beissert S, Werfel T, Frieling U et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007; 143: 1536–42.
- 43 Bystryn JC. Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid. Arch Dermatol 2008; 144: 946.
- 44 Meggitt SJ, Anstey AV, Mohd Mustapa MF et al. British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol 2011; 165: 711–34.
- 45 Hofmann SC, Kautz O, Hertl M et al. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009; 7: 227–33.
- 46 Fivenson DP, Breneman DL, Rosen GB et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753–8.
- 47 Thomas I, Khorenian S, Arbesfeld DM. Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol 1993; 28: 74–7.
- 48 Kawahara Y, Hashimoto T, Ohata Y et al. Eleven cases of bullous pemphigoid treated with a combination of minocycline and nicotinamide. Eur J Dermatol 1996; 6: 427–9.
- 49 Kolbach DN, Remme JJ, Bos WH et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol 1995; 133: 88–90.
- 50 Hornschuh B, Hamm H, Wever S et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol 1997; 36: 101–3.
- 51 Depaire-Duclos F, Dandurand M, Basset-Seguin N et al. Treatment of bullous pemphigoid with tetracyclines and topical corticosteroids. Eur J Dermatol 1997; 7: 570–3.
- 52 Safa G, Darrieux L. Nonbullous pemphigoid treated with doxycycline monotherapy: report of 4 cases. J Am Acad Dermatol 2011; 64: e116–18.
- 53 Fox BJ, Odom RB, Findlay RF. Erythromycin therapy in bullous pemphigoid: possible anti-inflammatory effects. J Am Acad Dermatol 1982; 7: 504–10.
- 54 Altomare G, Capella GL, Fracchiolla C et al. Treatment of bullous pemphigoid with erythromycin: a reappraisal. Eur J Dermatol 1999; 9: 583–5.
- 55 Mensing H, Krausse S. [Therapy of bullous pemphigoid with erythromycin]. Med Klin 1990; 85: 481–4 (in German).
- 56 Honl BA, Elston DM. Autoimmune bullous eruption localized to a breast reconstruction site: response to niacinamide. Cutis 1998; 62: 85–6.
- 57 Heilborn JD, Stahle-Backdahl M, Albertioni F et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40: 741–9.
- 58 Bara C, Maillard H, Briand N et al. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003; 139: 1506–7.
- 59 Du-Thanh A, Merlet S, Maillard H et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol 2011; 165: 1337–43.
- 60 Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008; 144: 612–16.
- 61 Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007; 20: 216–28.
- 62 Bohm M, Beissert S, Schwarz T et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997; 349: 541.
- 63 Grundmann-Kollmann M, Kaskel P, Leiter U et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 1999; 135: 724–5.
- 64 Phiamphonsongant T. Dapsone for the treatment of bullous pemphigoid. Asian Pacific J Allergy Immunol 1983; 1: 19–21.
- 65 Venning VA, Millard PR, Wojnarowska F. Dapsone as first-line therapy for bullous pemphigoid. Br J Dermatol 1989; 120: 83–92.
- 66 Bouscarat F, Chosidow O, Picard-Dahan C et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34: 683–4.
- 67 Person JR, Rogers RS 3rd. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977; 113: 610–15.
- 68 Jeffes EW, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol 1989; 14: 132–6.
- 69 Schmidt E, Kraensel R, Goebeler M et al. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis 2005; 76: 205–9.
- 70 Motegi S, Abe M, Tamura A et al. Childhood bullous pemphigoid successfully treated with diaminodiphenyl sulfone. J Dermatol 2005; 32: 809–12.
- 71 Marcus KA, Halbertsma FJ, van Steensel MA. A case of juvenile bullous pemphigoid – successful treatment with diaminodiphenylsulfone and prednisone. Pediatr Dermatol 2009; 26: 55–8.
- 72 Godard W, Roujeau JC, Guillot B et al. Bullous pemphigoid and intravenous gammaglobulin. Ann Intern Med 1985; 103: 964–5.
- 73 Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989; 20: 684–5.
- 74 Beckers RC, Brand A, Vermeer BJ et al. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995; 133: 289–93.
- 75 Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865–74.
- 76 Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 825–35.
- 77 Gaitanis G, Alexis I, Pelidou SH et al. High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid. Eur J Dermatol 2012; 22: 363–9.
- 78 Joint Formulary Committee. British National Formulary, vol. 63. London: British Medical Association and Royal Pharmaceutical Society, 2012.
- 79 Department of Health. Clinical Guidelines for Immunoglobulin use, 2nd edn. updated 2011. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085235 (last accessed 25 September 2012).
- 80 Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990; 22: 796–801.
- 81 Chave TA, Mortimer NJ, Shah DS et al. Chlorambucil as a steroid-sparing agent in bullous pemphigoid. Br J Dermatol 2004; 151: 1107–8.
- 82 Itoh T, Hosokawa H, Shirai Y et al. Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. Br J Dermatol 1996; 134: 931–3.
- 83 Dawe RS, Naidoo DK, Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol 1997; 137: 826–7.
- 84 Ogawa Y, Adachi A, Okamoto M et al. A case of refractory bullous pemphigoid with plasmapheresis-associated thrombopenia: efficacy of pulsed intravenous cyclophosphamide therapy. J Dermatol 2004; 31: 651–4.
- 85 Taieb A, Klene C, Maleville J. Immediate treatment of bullous pemphigus with a corticosteroid–cyclophosphamide combination. Ann Dermatol Venereol 1986; 113: 1223–9.
- 86 Barthelemy H, Thivolet J, Cambazard F et al. Cyclosporin in the treatment of bullous pemphigoid: preliminary study. Ann Dermatol Venereol 1986; 113: 309–13.
- 87 Chu J, Bradley M, Marinkovich MP. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 2003; 139: 813–15.
- 88 Chuh AA. The application of topical tacrolimus in vesicular pemphigoid. Br J Dermatol 2004; 150: 622–3.
- 89 Calcaterra R, Carducci M, Franco G et al. Topical tacrolimus treatment for localized pretibial bullous pemphigoid. J Eur Acad Dermatol Venereol 2009; 23: 177–9.
- 90 Ko MJ, Chu CY. Topical tacrolimus therapy for localized bullous pemphigoid. Br J Dermatol 2003; 149: 1079–81.
- 91 Lebeau S, Mainetti C, Masouye I et al. Localized childhood vulval pemphigoid treated with tacrolimus ointment. Dermatology 2004; 208: 273–5.
- 92 Schmidt E, Seitz CS, Benoit S et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352–6.
- 93 Schulze J, Bader P, Henke U et al. Severe bullous pemphigoid in an infant – successful treatment with rituximab. Pediatr Dermatol 2008; 25: 462–5.
- 94 Saouli Z, Papadopoulos A, Kaiafa G et al. A new approach on bullous pemphigoid therapy. Ann Oncol 2008; 19: 825–6.
- 95 Szabolcs P, Reese M, Yancey KB et al. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 2002; 30: 327–9.
- 96 Reguiai Z, Tchen T, Perceau G et al. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol 2009; 136: 431–4.
- 97 Lourari S, Herve C, Doffoel-Hantz V et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 2011; 25: 1238–40.
- 98 Kasperkiewicz M, Shimanovich I, Ludwig RJ et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65: 552–8.
- 99 Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006; 54: S121–2.
- 100 Boussemart L, Jacobelli S, Batteux F et al. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology 2010; 221: 201–5.
- 101 Stausbol-Gron B, Deleuran M, Sommer Hansen E et al. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol 2009; 34: e285–6.
- 102 Fairley JA, Baum CL, Brandt DS et al. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009; 123: 704–5.
- 103 Dufour C, Souillet AL, Chaneliere C et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol 2012; 166: 1140–2.
- 104 Mockenhaupt M, Grosber M, Norganer J. Daclizumab: a novel therapeutic option in severe bullous pemphigoid. Acta Derm Venereol 2005; 85: 65–6.
- 105 Tripodi G, Risso M, Tenerini L et al. Drug-resistant bullous pemphigoid and inflammatory bowel disease in a pediatric case successfully treated by plasma exchange and extracorporeal photochemotherapy. J Clin Apher 2007; 22: 26–30.
- 106 Hatano Y, Katagiri K, Arakawa S et al. Successful treatment by double-filtration plasmapheresis of a patient with bullous pemphigoid: effects in vivo on transcripts of several genes for chemokines and cytokines in peripheral blood mononuclear cells. Br J Dermatol 2003; 148: 573–9.
- 107 Mazzi G, Raineri A, Zanolli FA et al. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus Apher Sci 2003; 28: 13–18.
- 108 Herrero-Gonzalez JE, Sitaru C, Klinker E et al. Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption. Clin Exp Dermatol 2005; 30: 519–22.
- 109 Ino N, Kamata N, Matsuura C et al. Immunoadsorption for the treatment of bullous pemphigoid. Ther Apher 1997; 1: 372–6.
- 110 Muller PA, Brocker EB, Klinker E et al. Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatology 2012; 224: 224–7.
- 111 Fisler RE, Saeb M, Liang MG et al. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol 2003; 25: 183–9.
- 112 Waisbourd-Zinman O, Ben-Amitai D, Cohen AD et al. Bullous pemphigoid in infancy: clinical and epidemiologic characteristics. J Am Acad Dermatol 2008; 58: 41–8.
- 113 Edwards S, Wakelin SH, Wojnarowska F et al. Bullous pemphigoid and epidermolysis bullosa acquisita: presentation, prognosis, and immunopathology in 11 children. Pediatr Dermatol 1998; 15: 184–90.
- 114 Sugawara N, Nagai Y, Matsushima Y et al. Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy. J Am Acad Dermatol 2007; 57: 1084–9.
- 115 Xiao T, Li B, Wang YK et al. Childhood bullous pemphigoid treated by i.v. immunoglobulin. J Dermatol 2007; 34: 650–3.
- 116 Fox JC, Kenkare S, Petronic Rosic V et al. Bullous pemphigoid in late childhood successfully treated with mycophenolate mofetil as an adjuvant therapy. Pediatr Dermatol 2010; 27: 537–9.
